Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Boswellic Acids Improve Clinical Cognitive Scores and Reduce Systemic Inflammation in Patients With Mild to Moderate Alzheimer's Disease Publisher Pubmed



Karima S1 ; Aghamollaii V2 ; Mahmoodi Baram S3 ; Balenci L4 ; Lanctot KL5 ; Kiss A6 ; Tafakhori A7 ; Mahdavi M1 ; Rajaei S3 ; Shateri S1 ; Yarhoseini A2 ; Mokhtari F3 ; Fotouhi A8 ; Riazi A4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Neurology Department, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Clinical Trial Department, Behbalin Inc., Tehran, Iran
  4. 4. Kondor Pharma Inc., Mississauga, ON, Canada
  5. 5. Departments of Psychiatry and Pharmacology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, Canada
  6. 6. Department of Research Design and Biostatistics, Sunnybrook Research Institute, Toronto, Canada
  7. 7. Department of Neurology, School of Medicine, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Alzheimer's Disease Published:2023


Abstract

Background: Recent therapeutic approaches for Alzheimer's disease (AD) have had limited success. Considering the association of neuroinflammation with AD symptoms as demonstrated in multiple studies, assessment of the clinical efficacy of molecules that reduce systemic or brain inflammation is warranted. Objective: This clinical trial assessed whether boswellic acids can improve cognitive and neuropsychiatric symptoms while reducing inflammation in AD patients. Methods: A double-blind, placebo-controlled, study was conducted on 85 AD patients randomized to boswellic acids (K-Vie™ as the main ingredient in Memowell™) or placebo for 6 months. Clinical Dementia Rating-Sum of Boxes (CDR-SOB) and Mini-Mental State Examination (MMSE) scores were compared to baseline and between groups and constituted the co-primary clinical efficacy endpoints. Secondary outcomes included neuropsychiatric assessment (Neuropsychiatric Inventory-Questionnaire, NPI-Q) and assessment of AD and inflammation biomarkers. Results: Patients on K-Vie™ showed a 3.1- and 1.6-unit improvement in MMSE and CDR-SOB scores, respectively, when compared to patients on placebo. NPI-Q analysis revealed significant improvement in the K-Vie™ but not in the placebo group. Only mild gastrointestinal side effects were reported in a few patients. Patients on K-Vie™ showed improvement in plasma AD biomarkers and reduction of key inflammatory cytokines including IL-6 and TNF. Conclusion: Our results support the positive cognitive effects of boswellic acids by reducing the systemic inflammation. © 2023 - IOS Press. All rights reserved.
Related Docs
View other Related Docs
1. Boswellia Serrata Extract Shows Cognitive Benefits in a Double-Blind, Randomized, Placebo-Controlled Pilot Clinical Trial in Individuals Who Suffered Traumatic Brain Injury, Brain Injury (2022)
2. Early Diagnosis of Alzheimer’S Disease With Blood Test; Tempting But Challenging, International Journal of Molecular and Cellular Medicine (2023)
3. Functional Improvement and Immune-Inflammatory Cytokines Profile of Ischaemic Stroke Patients After Treatment With Boswellic Acids: A Randomized, Double-Blind, Placebo-Controlled, Pilot Trial, Inflammopharmacology (2019)
4. Boswellic Acids Reduce Systemic Inflammation in Patients With Moderate Covid-19 Through Modulation of Nf-Κb Pathway, Journal of Dietary Supplements (2025)
5. Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions, Journal of Neuropathology and Experimental Neurology (2019)
6. Beta-Amyloid-Dependent Mirnas As Circulating Biomarkers in Alzheimer’S Disease: A Preliminary Report, Journal of Molecular Neuroscience (2020)
7. The Effect of Insomnia on Development of Alzheimer's Disease, Journal of Neuroinflammation (2020)
8. Avicenna’S Pharmacological Approach to Memory Enhancement, Neurological Sciences (2017)
Experts (# of related papers)
View all Related Experts
Abbas Tafakhori (6)
Vajiheh Aghamollaii (4)
Other Related Docs
9. Validation Study of the Persian Version of Behavioral Pathology in Alzheimer’S Disease Rating Scale (Behave-Ad) and the Empirical Bhave-Ad (E-Behave-Ad), Applied Neuropsychology: Adult (2025)
10. Validation Study of the Persian Version of Behavioral Pathology in Alzheimer’S Disease Rating Scale (Behave-Ad) and the Empirical Bhave-Ad (E-Behave-Ad), Applied Neuropsychology:Adult (2023)
11. Exploring the Effect of Gut Microbiome on Alzheimer's Disease, Biochemistry and Biophysics Reports (2024)
12. Dendrosome-Encapsulated Beta-Boswellic Acid Boosts Expression of the Memory-Related Genes in the B65 Cell Line, Journal of Drug Delivery Science and Technology (2020)
13. Sensing of Alzheimer's Disease and Multiple Sclerosis Using Nano-Bio Interfaces, Journal of Alzheimer's Disease (2017)